Evidence-Based Taiwan Consensus Recommendations for the treatment of Parkinson's disease
- PMID: 37674429
Evidence-Based Taiwan Consensus Recommendations for the treatment of Parkinson's disease
Abstract
Parkinson's disease (PD) is a common and disabling neurodegenerative disorder with a prevalence set to double by 2030. People with PD present both motor symptoms (such as tremor, rigidity, slowness of movements, and postural instability) and non-motor symptoms (such as dementia, psychiatric symptoms, and sleep disturbances). The treatment of PD is challenging and is highly individualized. The Taiwan Movement Disorder Society (TMDS) has published its treatment recommendations for PD in 2017. Since then, because the advent of medical and device-aided therapy has developed rapidly, the TMDS has recognized the need to disseminate the updated knowledge about the management of PD. The TMDS acknowledges the importance of evidence-based medicine (EBM) in clinical practice. Therefore, we strive to align our treatment recommendations with EBM principles. Nevertheless, it still needs to be emphasized that therapeutic recommendations should always be tailored to the individual patient, based not only on an accurate understanding of the efficacy and side effect profile of available treatments (the primary focus of guidelines), but also the physician's judgment, patient's preference, and the regulations of national health insurance. To ensure that the updated Taiwan treatment suggestions are appropriate and feasible, the treatment guideline subcommittee of TMDS referred to the guidelines from the International Movement Disorder Society and other treatment suggestions from United States and Europe concerning the level of evidence, recommendation levels, clinical efficacy, and potential adverse reactions of therapeutics for the treatment of motor and non-motor symptoms of PD. By incorporating the latest research, international guidelines, and treatment suggestions, the TMDS aims to provide comprehensive and up-to-date recommendations for the management of PD in Taiwan. These recommendations serve as a valuable resource for healthcare professionals to enhance their understanding of PD treatment options and optimize patient care. Key Words: Parkinson's disease; treatment; guidelines; evidence-based medicine.
Similar articles
-
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease.Transl Neurodegener. 2016 Jun 30;5:12. doi: 10.1186/s40035-016-0059-z. eCollection 2016. Transl Neurodegener. 2016. PMID: 27366321 Free PMC article. Review.
-
European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.Mov Disord. 2022 Jul;37(7):1360-1374. doi: 10.1002/mds.29066. Epub 2022 Jul 6. Mov Disord. 2022. PMID: 35791767 Review.
-
European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies.Eur J Neurol. 2022 Sep;29(9):2580-2595. doi: 10.1111/ene.15386. Epub 2022 Jul 6. Eur J Neurol. 2022. PMID: 35791766
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
Cited by
-
Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson's disease: a narrative review and expert opinion.Ther Adv Neurol Disord. 2025 Apr 17;18:17562864251329099. doi: 10.1177/17562864251329099. eCollection 2025. Ther Adv Neurol Disord. 2025. PMID: 40291755 Free PMC article. Review.
-
Curcumin as a potential therapeutic agent for Parkinson's disease: a systematic review.Front Pharmacol. 2025 Apr 22;16:1593191. doi: 10.3389/fphar.2025.1593191. eCollection 2025. Front Pharmacol. 2025. PMID: 40331193 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical